Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Pierre Fabre Partners with Iktos on AI-Driven Oncology Drug Discovery

Fineline Cube Jan 12, 2026
Company Deals

Haisco Licenses COPD Drug HSK39004 to AirNexis for $1.06 Billion

Fineline Cube Jan 12, 2026
Company Deals

Novartis Secures Exclusive Rights to Zonsen PepLib’s Radioligand Asset

Fineline Cube Jan 12, 2026
Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Fineline Cube Jan 11, 2026
Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Fineline Cube Jan 11, 2026
Policy / Regulatory

NHSA Launches Personal Healthcare Insurance Cloud Pilot Program

Fineline Cube Jan 12, 2026
Company Drug

Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets

Fineline Cube Jan 12, 2026
Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Fineline Cube Jan 11, 2026
Company Deals

Epigenic Therapeutics Secures $32 Million in Series A Funding for Gene Modulation Therapy

Fineline Cube Aug 30, 2023

Epigenic Therapeutics, a Shanghai-based biotech company specializing in gene modulation therapy through epigenome regulation, has...

Company Deals

Biocytogen Pharmaceuticals’ Eucure Biopharma Expands Partnership with Syncromune on Immunotherapies

Fineline Cube Aug 30, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd’s (HKG: 2315) wholly owned subsidiary, Eucure Biopharma, has announced...

Company Drug

CSPC Pharmaceutical’s Biosimilar Ozempic Equivalent Gets NMPA Clinical Trial Approval

Fineline Cube Aug 30, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its biosimilar version of Novo...

Company Drug

Jiangsu Yahong Meditech Gets NMPA Approval for APL1401 Ulcerative Colitis Trial

Fineline Cube Aug 30, 2023

Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176), a specialist in urogenital cancer based in...

Company

Luye Pharma Group Reports H1 2023 Revenue Growth with Strong Oncology and CNS Sales

Fineline Cube Aug 30, 2023

China-based Luye Pharma Group (HKG: 2186) has announced its financial performance for the first half...

Company

Fosun Pharma Reports Moderate Revenue Growth and Increased R&D Spend in 2023 Interim Report

Fineline Cube Aug 30, 2023

Fosun Pharma (SHA: 600196) has released its 2023 interim financial report, recording revenues of RMB...

Company Drug

Roche’s Evrysdi Receives EC Approval for Expanded Indication in Infants with SMA

Fineline Cube Aug 30, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has received regulatory approval from the European Commission (EC)...

Company Drug

MSD’s Keytruda Gains EC Approval for First-Line HER2-Positive Gastric Cancer Treatment

Fineline Cube Aug 30, 2023

The European Commission (EC) has granted an additional indication to Merck, Sharp & Dohme (MSD;...

Company Drug

BMS’ Reblozyl Expands Indication to Include First-Line MDS-Related Anemia Treatment

Fineline Cube Aug 30, 2023

Bristol-Myers Squibb (BMS; NYSE: BMY) has received an indication extension approval from the US Food...

Company Policy / Regulatory

HHS Releases List of 10 Drugs for Medicare Price Negotiations Starting 2026

Fineline Cube Aug 30, 2023

The Department of Health and Human Services (HHS) in the US has released a list...

Company Drug

ImmunoTech Biopharm’s EAL Earns Breakthrough Therapy Designation for HCC Recurrence Prevention

Fineline Cube Aug 29, 2023

The Center for Drug Evaluation (CDE) in China has indicated on its website that Immunotech...

Company Deals

Mabwell Bioscience Secures Deal with UNILAB for Biosimilar Humira in the Philippines

Fineline Cube Aug 29, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a licensing and supply agreement...

Company Deals

HanchorBio and Henlius Pharmaceutical Enter Strategic Collaboration for Immunotherapies

Fineline Cube Aug 29, 2023

Taiwan-based HanchorBio has entered into a strategic cooperation framework agreement with Shanghai-headquartered Shanghai Henlius Biotech,...

Company Medical Device

Novocure’s TTFields Misses Overall Survival Endpoint in Ovarian Cancer Phase III Trial

Fineline Cube Aug 29, 2023

Switzerland-based Novocure (NASDAQ: NVCR) has experienced a setback with its Tumor Treating Fields (TTFields) product,...

Company Drug

Harbour BioMed’s HBM9033 ADC Receives US FDA IND Clearance for Clinical Trials

Fineline Cube Aug 29, 2023

China-based Harbour BioMed (HKG: 2142) has announced receiving Investigational New Drug (IND) clearance from the...

Company Deals

Sandoz Expands Anti-Infective Portfolio with Acquisition of Astellas Pharma’s Antifungal Mycamine

Fineline Cube Aug 29, 2023

Switzerland-based Novartis (NYSE: NVS) subsidiary Sandoz has bolstered its global anti-infectives portfolio with the acquisition...

Company Deals

BMS Partners with Cellares for Automated CAR-T Cell Therapy Production

Fineline Cube Aug 29, 2023

Pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into an agreement with cell therapy...

Company Deals

Takeda and BridGene Biosciences Achieve Milestone in Neurodegenerative Disorder Target Identification

Fineline Cube Aug 29, 2023

A 2021 collaboration between Japan’s Takeda (TYO: 4502) and US-based BridGene Biosciences has successfully reached...

Company

Lundbeck A/S Reports 10% H1 2023 Revenue Increase with Record-Breaking Sales

Fineline Cube Aug 29, 2023

Denmark-based biopharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF) has released its financial report for the...

Company Drug

Janssen Submits Indication Extension Application for Balversa in Urothelial Carcinoma Treatment

Fineline Cube Aug 29, 2023

The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has submitted an indication extension...

Posts pagination

1 … 422 423 424 … 607

Recent updates

  • Dongcheng Pharma’s PSMA PET Agent [18F] Spiritide NDA Accepted by NMPA
  • Novartis to Build $23 Billion RLT Facility in Florida, Expanding Cancer Therapy Capacity
  • Pierre Fabre Partners with Iktos on AI-Driven Oncology Drug Discovery
  • NHSA Launches Personal Healthcare Insurance Cloud Pilot Program
  • China Expands Medical Insurance Personal Account Pooling Nationwide
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Medical Device

Dongcheng Pharma’s PSMA PET Agent [18F] Spiritide NDA Accepted by NMPA

Company

Novartis to Build $23 Billion RLT Facility in Florida, Expanding Cancer Therapy Capacity

Company Deals

Pierre Fabre Partners with Iktos on AI-Driven Oncology Drug Discovery

Policy / Regulatory

NHSA Launches Personal Healthcare Insurance Cloud Pilot Program

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.